We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-4%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.61B
AUM Growth
-$467M
Cap. Flow
-$348M
Cap. Flow %
-9.63%
Top 10 Hldgs %
67.4%
Holding
42
New
6
Increased
7
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$135M
2
CVS icon
CVS Health
CVS
+$93.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$70.8M
4
MDT icon
Medtronic
MDT
+$32.8M
5
ARGX icon
argenx
ARGX
+$27.6M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$200M
2
BIIB icon
Biogen
BIIB
+$86.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$55.9M
4
UHS icon
Universal Health Services
UHS
+$53.1M
5
MYGN icon
Myriad Genetics
MYGN
+$46.8M

Sector Composition

Rank Sector Weight
1 Healthcare 70.02%
2 Consumer Staples 1.05%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$952M 26.36%
1,750,000
-450,000
-20% -$236M
ZBH icon
2
Zimmer Biomet
ZBH
$18.8B
$209M 5.78%
1,925,000
– –
BAX icon
3
Baxter International
BAX
$12.8B
$184M 5.09%
5,500,000
+500,000
+10% +$18.4M
MDT icon
4
Medtronic
MDT
$112B
$177M 4.9%
2,250,000
+400,000
+22% +$32.8M
UHS icon
5
Universal Health Services
UHS
$10.2B
$176M 4.86%
950,000
-300,000
-24% -$53.1M
GMED icon
6
Globus Medical
GMED
$11.1B
$171M 4.74%
2,500,000
– –
VTRS icon
7
Viatris
VTRS
$20.8B
$159M 4.41%
15,000,000
-1,250,000
-8% -$13.8M
HUM icon
8
Humana
HUM
$43.9B
$149M 4.14%
+400,000
New +$135M
MYGN icon
9
Myriad Genetics
MYGN
$476M
$135M 3.72%
5,500,000
-2,135,000
-28% -$46.8M
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$16.1B
$123M 3.4%
1,150,000
– –
PTCT icon
11
PTC Therapeutics
PTCT
$6.18B
$107M 2.96%
3,500,000
-500,000
-13% -$16.2M
BKD icon
12
Brookdale Senior Living
BKD
$3.55B
$106M 2.93%
15,500,000
– –
GSK icon
13
GSK
GSK
$107B
$103M 2.85%
2,675,000
+500,000
+23% +$21M
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$11.9B
$90.6M 2.51%
1,100,000
+850,000
+340% +$70.8M
SEM
15
DELISTED
Select Medical
SEM
$89.4M 2.47%
4,732,800
-1,577,600
-25% -$26.9M
CVS icon
16
CVS Health
CVS
$135B
$88.6M 2.45%
+1,500,000
New +$93.8M
WBA
17
DELISTED
Walgreens Boots Alliance
WBA
$84.7M 2.34%
7,000,000
-800,000
-10% -$13.6M
PFE icon
18
CALL
Pfizer
PFE
$143B
$70M 1.94%
2,500,000
– –
QGEN icon
19
Qiagen
QGEN
$8.62B
$61.6M 1.71%
1,458,333
+281,944
+24% +$12.4M
ZIMV
20
DELISTED
ZimVie
ZIMV
$59.3M 1.64%
3,250,000
– –
DNLI icon
21
Denali Therapeutics
DNLI
$3.79B
$46.4M 1.29%
2,000,000
+500,000
+33% +$9.6M
PRGO icon
22
Perrigo
PRGO
$1.44B
$39M 1.08%
1,520,000
– –
HLF icon
23
Herbalife
HLF
$1.3B
$31.2M 0.86%
3,000,000
– –
ARGX icon
24
argenx
ARGX
$55.2B
$31M 0.86%
+72,000
New +$27.6M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.64B
$23.7M 0.66%
150,000
-435,000
-74% -$55.9M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Camber Capital Management held 42 positions worth $3.61B, down 11% from $4.08B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Camber Capital Management withdrew a net $348M in Q2 2024, closing 5 positions and reducing 10 holdings. Its most notable exit was Tenet Healthcare, an estimated $200M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 68% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Camber Capital Management opened a new position in Humana worth $149M.

  • Camber Capital Management's largest Q2 2024 buy was Humana: 400,000 shares worth $149M.
  • Camber Capital Management added most to BioMarin Pharmaceuticals in Q2 2024, an estimated $70.8M increase.
  • Camber Capital Management's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $55.9M.
  • Camber Capital Management fully exited Tenet Healthcare in Q2 2024, selling an estimated $200M.
  • Camber Capital Management's ten largest holdings make up 67% of its $3.61B portfolio in Q2 2024.
  • Camber Capital Management opened 6 new positions and closed 5 in Q2 2024.
  • Camber Capital Management's portfolio value fell 11% quarter-over-quarter to $3.61B.

Based on Camber Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.